/KALV
KALV Stock - KalVista Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$15.23+1.53%
+$0.23 (+1.53%) • Dec 19
87
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.88
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+83.8%upside
Target: $27.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KALV
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$15.08 – $15.38
TARGET (TP)$28.00
STOP LOSS$14.01
RISK/REWARD1:10.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.14
52W High$17.30
52W Low$7.30
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-86,167,000 | N/A | N/A | $-41,286,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-187,995,000 | $-140,445,000 | $-110,871,000 | $-96,613,000 | $-57,923,000 |
| Net Income | $-183,444,000 | $-126,644,000 | $-92,907,000 | $-82,339,000 | $-46,244,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.69 | $-3.44 | $-3.33 | $-3.36 | $-2.33 |
Company Overview
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$24
Average Target
↑ 55.4% Upside
Now
$19
Low
$24
Average
$30
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 31st 2025 | JMP Securities | Initiation | Mkt Outperform | $19 |
| January 7th 2025 | TD Cowen | Initiation | Buy | $30 |
| December 18th 2024 | BofA Securities | Initiation | Buy | $22 |
Earnings History & Surprises
KALVBeat Rate
47%
Last 19 quarters
Avg Surprise
-1.7%
EPS vs Estimate
Beats / Misses
9/9
1 met exactly
Latest EPS
$-0.92
Q4 2025
EPS Surprise History
Q1 24
-12.4%
$-0.84vs$-0.75
Q3 24
-43.7%
$-1.02vs$-0.71
Q3 24
+8.4%
$-0.87vs$-0.95
Q4 24
0.0%
$-0.91vs$-0.91
Q1 25
-3.4%
$-0.92vs$-0.89
Q3 25
-28.6%
$-0.99vs$-0.77
Q3 25
-23.1%
$-1.12vs$-0.91
Q4 25
+4.2%
$-0.92vs$-0.96
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 10, 2026 | — | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.96 | $-0.92 | +4.2% | ✓ BEAT |
Q3 2025 | Sep 11, 2025 | $-0.91 | $-1.12 | -23.1% | ✗ MISS |
Q3 2025 | Jul 10, 2025 | $-0.77 | $-0.99 | -28.6% | ✗ MISS |
Q1 2025 | Mar 12, 2025 | $-0.89 | $-0.92 | -3.4% | ✗ MISS |
Q4 2024 | Dec 5, 2024 | $-0.91 | $-0.91 | 0.0% | = MET |
Q3 2024 | Sep 5, 2024 | $-0.95 | $-0.87 | +8.4% | ✓ BEAT |
Q3 2024 | Jul 11, 2024 | $-0.71 | $-1.02 | -43.7% | ✗ MISS |
Q1 2024 | Mar 11, 2024 | $-0.75 | $-0.84 | -12.4% | ✗ MISS |
Q4 2023 | Dec 7, 2023 | $-0.71 | $-0.80 | -12.7% | ✗ MISS |
Q3 2023 | Sep 7, 2023 | $-0.83 | $-0.74 | +10.8% | ✓ BEAT |
Q3 2023 | Jul 7, 2023 | $-0.92 | $-0.77 | +16.3% | ✓ BEAT |
Q1 2023 | Mar 9, 2023 | $-0.97 | $-0.75 | +22.7% | ✓ BEAT |
Q4 2022 | Dec 8, 2022 | $-1.04 | $-0.90 | +13.5% | ✓ BEAT |
Q3 2022 | Sep 8, 2022 | $-1.02 | $-0.94 | +7.8% | ✓ BEAT |
Q3 2022 | Jul 7, 2022 | $-1.06 | $-0.98 | +7.5% | ✓ BEAT |
Q1 2022 | Mar 10, 2022 | $-0.91 | $-0.92 | -1.1% | ✗ MISS |
Q4 2021 | Dec 9, 2021 | $-0.78 | $-0.80 | -2.6% | ✗ MISS |
Q3 2021 | Sep 9, 2021 | $-0.73 | $-0.66 | +9.6% | ✓ BEAT |
Q3 2021 | Jul 13, 2021 | $-0.61 | $-0.65 | -6.6% | ✗ MISS |
Latest News
Needham Reiterates Buy on KalVista Pharmaceuticals, Maintains $28 Price Target
📈 PositiveBenzinga•Dec 4, 2025, 10:49 AM
Citizens Maintains Market Outperform on KalVista Pharmaceuticals, Lowers Price Target to $28
➖ NeutralBenzinga•Nov 11, 2025, 01:49 PM
KalVista Pharma Q3 EPS $(0.92) Beats $(1.01) Estimate, Sales $13.692M Beat $4.758M Estimate
📈 PositiveBenzinga•Nov 10, 2025, 09:39 PM
KalVista Pharmaceuticals Releases New Clinical And Survey Data For EKTERLY Showing It Provides Early, Effective, And Safe Treatment Of HAE Attacks In Pediatric Patients
📈 PositiveBenzinga•Nov 6, 2025, 01:36 PM
KalVista Pharmaceuticals Presents Data From KONFIDENT Studies On EKTERLY For Hereditary Angioedema, Highlights Need For Oral Alternatives To Injectable Therapies
📈 PositiveBenzinga•Oct 6, 2025, 08:03 PM
KalVista Pharma Appoints Bilal Arif As COO, Effective October 6, 2025
➖ NeutralBenzinga•Oct 6, 2025, 11:01 AM
KalVista Pharmaceuticals To Present Six EKTERLY (Sebetralstat) EPosters For Hereditary Angioedema At 20th German Allergy Congress In Düsseldorf, Oct 2–4, 2025
📈 PositiveBenzinga•Sep 26, 2025, 11:03 AM
KalVista shares are trading lower after the company priced an upsized $125 million offering of 3.25% convertible senior notes due 2031.
📉 NegativeBenzinga•Sep 25, 2025, 03:46 PM
Reported Earlier, KalVista Prices Upsized $125M Offering Of 3.250% Convertible Senior Notes Due 2031, Increased From $110M Previously Announced
➖ NeutralBenzinga•Sep 25, 2025, 06:22 AM
KalVista to offer $110M in convertible notes; shares down 10%
📉 NegativeSeeking Alpha•Sep 24, 2025, 08:25 PM
KalVista Pharmaceuticals shares are trading lower after the company announced a $110 million private offering.
📉 NegativeBenzinga•Sep 24, 2025, 08:21 PM
KalVista Pharmaceuticals Announces $110M Private Offering Of Convertible Senior Notes Due 2031
➖ NeutralBenzinga•Sep 24, 2025, 08:05 PM
KalVista Pharma Says EC And Swissmedic Approve EKTERLY, Oral Plasma Kallikrein Inhibitor, For Symptomatic Treatment Of Acute Attacks Of HAE In Adults
📈 PositiveBenzinga•Sep 19, 2025, 11:02 AM
Needham Reiterates Buy on KalVista Pharmaceuticals, Maintains $28 Price Target
📈 PositiveBenzinga•Sep 12, 2025, 01:39 PM
JMP Securities Maintains Market Outperform on KalVista Pharmaceuticals, Raises Price Target to $28
📈 PositiveBenzinga•Sep 12, 2025, 11:05 AM
KalVista Posts 154% Expense Jump in Q1
📉 NegativeThe Motley Fool•Sep 11, 2025, 08:25 PM
KalVista Pharma Q1 EPS $(1.12) Misses $(0.95) Estimate, Sales $1.426M Miss $2.089M Estimate
📉 NegativeBenzinga•Sep 11, 2025, 11:01 AM
KalVista Pharmaceuticals rises after FDA nod for Ekterly
📈 PositiveSeeking Alpha•Jul 7, 2025, 02:06 PM
Frequently Asked Questions about KALV
What is KALV's current stock price?
KalVista Pharmaceuticals, Inc. (KALV) is currently trading at $15.23 per share. The stock has moved +1.53% today.
What is the analyst price target for KALV?
The average analyst price target for KALV is $28.00, based on 1 analyst.
What sector is KalVista Pharmaceuticals, Inc. in?
KalVista Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is KALV's market cap?
KalVista Pharmaceuticals, Inc. has a market capitalization of $0.77 billion, making it a small-cap company.
Does KALV pay dividends?
No, KalVista Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADCT
ADC Therapeutics S.A.
$3.73
Mkt Cap: $0.4B
BCYC
Bicycle Therapeutics plc
$6.87
Mkt Cap: $0.5B
FDMT
4D Molecular Therapeutics, Inc.
$8.68
Mkt Cap: $0.4B
GOSS
Gossamer Bio, Inc.
$3.44
Mkt Cap: $0.8B
OLMA
Olema Pharmaceuticals, Inc.
$27.93
Mkt Cap: $1.9B
OMER
Omeros Corporation
$9.60
Mkt Cap: $0.7B
PRTA
Prothena Corporation plc
$9.21
Mkt Cap: $0.5B
RAPT
RAPT Therapeutics, Inc.
$33.81
Mkt Cap: $0.6B
RIGL
Rigel Pharmaceuticals, Inc.
$41.59
Mkt Cap: $0.7B
VSTM
Verastem, Inc.
$7.76
Mkt Cap: $0.5B
Explore stocks similar to KALV for comparison